SEP 02, 2021 7:00 AM PDT

Hobit Activates Cancer-Killing Immune Cells

WRITTEN BY: Tara Fernandez

Innate lymphoid cells, or ILCs, are specialized immune cells that are increasingly entering the research spotlight. These cells mirror many of the characteristics and functions of T cells. In contrast, however, ILCs do not have antigen receptors on their cell surfaces, nor do they migrate to the site of infection and expand in numbers when stimulated by the presence of pathogens. Instead, ILCs stay put in tissues and organs where they churn out an inflammatory cocktail of cytokines in response to tissue injury or infection.

These powerful immune functions can be harnessed therapeutically. But first, scientists must find a missing piece in the ILC puzzle: how these cells differentiate and mature into fully-fledged immune warriors.

Georg Gasteiger and colleagues at the Max Planck Research Group set out in search of answers, seeking to more deeply understand how immature ILCs turn into operational effector cells capable of killing malignant or infected cells. The researchers took a closer look at a subpopulation of liver ILCs known to be involved in both these immune processes, creating a genetic atlas of mRNA molecules extracted and compiled from individual lLCs.

Among the team’s breakthrough findings was the observation that a cohort of ‘supply’ ILCs resided within tissues. These cells can multiply rapidly upon sensing danger and differentiate into killer ILCs, a process driven by a transcription factor gene called Hobit. These immune killers have specific molecular signatures that enable them to recognize and eliminate cancer effectively.

These findings contradict what the textbooks say about ILCs—that ILCs consist of a heterogeneous mix of different cell types. Instead, Gasteiger and colleagues demonstrate different degrees of specialization in ILCs, which stem from a single population of supply cells.

The team plans to continue delving into the mysterious world of ILC biology, seeking clues on activating killer ILCs therapeutically to eradicate tumors and cancer metastases developing within tissues. Moreover, because Hobit is expressed in other cytotoxic cells of the human immune system, understanding the role of this transcription factor in modulating other immune effects may help unlock novel mechanisms for fighting cancer in different tissues.

Source: Nature Immunology.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUN 07, 2021
Health & Medicine
Higher Incidence of Breast Cancer in Polluted Urban Areas
JUN 07, 2021
Higher Incidence of Breast Cancer in Polluted Urban Areas
A Taiwanese study looked at the incidence of breast cancer in areas of Taiwan with varying levels of air pollutants. Air ...
JUL 29, 2021
Drug Discovery & Development
What is Ivermectin and Can it Treat COVID?
JUL 29, 2021
What is Ivermectin and Can it Treat COVID?
Lab tests in 2020 found that the widely available drug ivermectin had a weak effect on the SARS-CoV-2 virus and that unf ...
AUG 10, 2021
Immunology
An Immune Molecule Helps Create 'Good' Fat
AUG 10, 2021
An Immune Molecule Helps Create 'Good' Fat
Not all fat is ‘bad’—there’s white fat that builds up when excess calories are consumed. But, th ...
AUG 19, 2021
Cancer
Japanese Berry Vine Could Treat Lung Cancer
AUG 19, 2021
Japanese Berry Vine Could Treat Lung Cancer
A berry-producing vine in Japan has shown promise in mouse models for treating lung cancer. The corresponding study was ...
AUG 24, 2021
Health & Medicine
Myocarditis and COVID-19 Vaccination
AUG 24, 2021
Myocarditis and COVID-19 Vaccination
Myocarditis has been linked to sudden cardiac death in young, healthy athletes and smallpox, influenza, hepatitis B, and ...
SEP 07, 2021
Immunology
Designer Cells for Treating Arthritis Are Activated by Inflammation
SEP 07, 2021
Designer Cells for Treating Arthritis Are Activated by Inflammation
Scientists have developed a new cell therapy for arthritis that becomes activated in the presence of inflammation. When ...
Loading Comments...